The Regulatory Journey of Moderna’s mRNA Flu Shot

Moderna is on the brink of discovering whether the FDA will approve its mRNA flu shot. Health Secretary Robert F. Kennedy Jr. has often questioned the efficacy of mRNA vaccines. Now, the FDA’s decision will be pivotal for future mRNA research and applications.

In February, Moderna’s president Stephen Hoge encountered a tense situation at a manufacturing site when Charbel Haber, responsible for regulatory affairs, conveyed a troubling update. The FDA had sent a letter refusing to review Moderna’s flu shot application, catching the company off guard despite previous assurances of review. This unexpected rejection was a blow to Moderna, which had engaged in regular dialogue with the FDA during the process.

The FDA’s decision resonated throughout the pharmaceutical industry, sparking concerns over the agency’s change in stance.

Within a short timeframe, public outcry led the FDA to reconsider its position. Moderna agreed to integrate a confirmatory study into its research, intriguing the FDA enough to reassess the application. Consequently, an FDA advisory panel recommended approval of the vaccine in June. A looming Wednesday deadline now clocks the FDA’s decision. Should approval occur, Moderna’s offering could become the first mRNA-based flu shot available commercially.

Rena Conti, a health economist, notes that the industry will observe closely, as the U.S. market represents their primary source of revenue. Companies need consistency from the FDA to ensure profitability in future ventures.

Last summer, HHS canceled nearly $500 million in mRNA research funding. An HHS spokesman asserted the administration’s commitment to public health via science-based policies and innovation. Despite this, uncertainty looms among mRNA investors.

Jeff Coller from Johns Hopkins University acknowledges Moderna as a leader in the mRNA field. His concern lies with smaller biotech companies, worried about regulatory barriers after seeing Moderna’s initial rejection.

Case in point: Janusz Racz, a retired computer scientist in London, battled Stage 3 lung cancer with BioNTech’s mRNA vaccine. As the first UK recipient, Racz watched his cancer disappear, nurturing hope for a future. Nevertheless, he noted opposition from the current administration against mRNA vaccines.

Racz, a U.S. citizen, even reached out to Secretary Kennedy, advocating the life-saving potential of mRNA technologies. His letter went unanswered.